WARF: P08343US

  • Assigned to WARF as biological material.

Novel Analogs of Podophyllotoxin May Treat Cancer and Viral Infections


Jon Thorson, James Watson, Jr.

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing novel compounds with anticancer and antiviral activity.
OVERVIEWPodophyllotoxin is a natural product derived from a plant. Although two clinically useful glycosylated analogs have been developed for treating cancer, podophyllotoxin is difficult to synthesize, hindering efforts to optimize the sugars on the parent molecule and maximize efficacy.

UW–Madison researchers previously developed a method, known as neoglycorandomization, for adding sugars to natural products to create a library of compounds for screening. The approach uses a universal chemical glycosylation method that employs reducing sugars and requires no protection or activation.
THE INVENTIONUW–Madison researchers have now synthesized a library of podophyllotoxin derivatives using the neoglycorandomization method. The new derivatives may be useful for treating cancer or as antivirals.
  • Cancer treatment
  • Antivirals
  • Novel compounds
  • Derived from a natural product
Contact Information
For current licensing status, please contact Rafael Diaz at or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.